Synlogic

Synlogic is a clinical-stage biopharmaceutical company that focuses on developing novel therapies to transform the care of serious diseases. The company's primary focus is on rare metabolic diseases, particularly phenylketonuria (PKU) and classical homocystinuria (HCU). Synlogic's approach is to design and develop living therapeutics, called Synthetic Biotics, which are engineered probiotics designed to address the underlying drivers of these diseases. These Synthetic Biotics are GI-restricted, orally administered, and capable of consuming or modifying disease-specific metabolites.

Synlogic's pipeline includes several drug candidates at various stages of development. Their lead program, labafenogene marselecobac (SYNB1934), is currently being studied in a global, pivotal Phase 3 study for patients with PKU. Other promising drug candidates in their pipeline include SYNB1353, a potential treatment for HCU, and SYNB8802, a candidate for enteric hyperoxaluria. Synlogic is also exploring the potential for Synthetic Biotic approaches to treat gout, cystinuria, and inflammatory bowel disease. The company leverages its proprietary platform and expertise in synthetic biology to develop these innovative therapeutic options.

Synlogic is a biopharmaceutical company dedicated to developing novel therapeutics to transform the care of serious diseases. They specialize in the development of "Synthetic Biotics," which are living organisms designed to impact specific functions in the body to treat disease. By combining expertise in molecular biology, microbial engineering, and physiology, Synlogic pioneers the application of synthetic biology to create first-in-class biotherapeutics, with a particular focus on rare metabolic diseases and other conditions where current treatment options are limited.

Synlogic promotes a collaborative and people-focused culture where they value compassion, trust, and fun. This is further emphasized by the company's "Core Values" section, where they highlight their commitment to nurturing talent, professional growth, and driving meaningful careers and lives.

Synlogic's commitment to diversity, equity, and inclusion is evident in their efforts to foster a people-focused environment grounded in compassion, trust, collaboration, and fun. Their focus on nurturing talent and personal and professional growth aims to drive meaningful careers and lives, while prioritizing a culture of inclusivity, where everyone feels valued and respected. They demonstrate their commitment to transparency through the public sharing of their Board Diversity Matrix, showcasing the representation of diverse backgrounds within their leadership.